Currently out of the existing stock ratings of Srikripa Devarakonda, 33 are a BUY (100%).

Srikripa Devarakonda

Work Performance Price Targets & Ratings Chart

Analyst Srikripa Devarakonda, currently employed at TRUIST, carries an average stock price target met ratio of 19.44% that have a potential upside of 27.7% achieved within 81 days.

Srikripa Devarakonda’s has documented 69 price targets and ratings displayed on 9 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on KYMR, Kymera Therapeutics at 01-Nov-2024.

Wall Street Analyst Srikripa Devarakonda

Analyst best performing recommendations are on KYMR (KYMERA THERAPEUTICS).
The best stock recommendation documented was for KYMR (KYMERA THERAPEUTICS) at 11/3/2023. The price target of $41 was fulfilled within 112 days with a profit of $26.73 (187.32%) receiving and performance score of 16.72.

Average potential price target upside

INCY yte AFMD Affimed NV CNST Constellation Pharmaceuticals NMTR 9 Meters Biopharma VSTM Verastem CYTK Cytokinetics KROS Keros Therapeutics  KYMR Kymera Therapeutics LLY Eli Lilly and Company

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$74

$2.28 (3.18%)

$80

7 days ago
(19-Nov-2024)

27/39 (69.23%)

$5.55 (8.11%)

202

Hold

$69

$-2.72 (-3.79%)

$64

27 days ago
(30-Oct-2024)

19/20 (95%)

$-4.93 (-6.67%)

154

Hold

$71

$-0.72 (-1.00%)

$65

27 days ago
(30-Oct-2024)

6/7 (85.71%)

$-2.93 (-3.96%)

108

Hold

$70

$-1.72 (-2.40%)

$65

27 days ago
(30-Oct-2024)

5/11 (45.45%)

$-3.93 (-5.32%)

119

Hold

$68

$-3.72 (-5.19%)

$62

27 days ago
(30-Oct-2024)

3/5 (60%)

$-5.93 (-8.02%)

28

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Srikripa Devarakonda is most bullish on?

Potential upside of $284.99 has been obtained for LLY (ELI LILLY AND COMPANY)

Which stock is Srikripa Devarakonda is most reserved on?

Potential downside of $2.28 has been obtained for INCY (YTE)

What Year was the first public recommendation made by Srikripa Devarakonda?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?